SynthesisBlood advances2025
Chronic kidney disease in adults with sickle cell trait: a systematic review and meta-analysis.
Synthesis in Blood advances, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Phenome- and laboratory-wide meta-analyses of sickle cell trait reveal multi-system disease associations.American journal of human genetics · 2026Pooled it
- The Metabolomic Landscape of Sickle Cell Trait Nephropathy: Illuminating an Under-Recognized Problem.Clinical journal of the American Society of Nephrology : CJASN · 2026Article
- Performance of creatinine and cystatin C-based equations for estimating high levels of glomerular filtration rate in Congolese adults with sickle cell disease.Clinical kidney journal · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
abstractSickle cell trait (SCT) may increase the risk of chronic kidney disease (CKD). We aimed to determine the pooled statistics of the association between SCT and CKD. Studies published up to May 2024 that were available on PubMed, Embase, Global Health Library, and Web of Science were screened. We included studies that reported odds ratios or hazard ratios (HRs) of CKD and/or end-stage renal disease (ESRD) and that compared adults with SCT to those without SCT. The risk of bias was evaluated using the Risk Of Bias In Nonrandomized Studies-of Exposures tool. The pooled SCT prevalence was calculated among patients with CKD/ESRD. A random-effects analysis was performed. Only studies with low or some concerns of bias were included, corresponding to 18 847 participants with SCT and 1 060 818 without SCT. Participants with SCT had higher odds of having an estimated glomerular filtration rate (eGFR) of ≤60 mL/min per 1.73 m2, proteinuria, and eGFR ≤60 mL/min per 1.73 m2 and/or proteinuria. The pooled prevalence of SCT among African American individuals with ESRD was 10%; however, the heterogeneity was very high (I2, 85.6%). There was a higher HR for ESRD in the studies that included both males and females than in the study that included only females, suggesting that males have a higher risk of ESRD. Controversial results were observed for the association of CKD with hypertension and diabetes. SCT increases the risk of developing CKD and ESRD. PROSPERO registration: CRD42021275274.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.